Bayer, BioNxt Solutions, Novo Nordisk – The pressure is on

Bayer – Shock at the end of the week

It was a horror week for the pharmaceutical and agricultural giant from Leverkusen. Not only did Bayer's football team virtually say goodbye to the Champions League and the championship after a 3-0 defeat against FC Bayern and the subsequent 1-0 home defeat against Augsburg. Even more significant is that the Bayer share price fell by more than 8% at the end of the week after a previous recovery rally. At the close of trading on Friday, it was down 6.5% at EUR 23.25. This meant that the short-term upward trend that had emerged at the end of December 2024 was defended, but both the MACD trend-following indicator and the RSI turned to "Sell", suggesting further downside potential.

The reason for the renewed sell-off was once again the glyphosate litigation, which has been a recurring theme for years. Given the tens of thousands of lawsuits, Bayer wants to protect itself with a capital increase to create a risk buffer for settling the legal disputes. The volume, which could amount to up to 35% of the Company's share capital, currently totaling EUR 2.5 billion, appears extremely high.

In the invitation for the Annual General Meeting scheduled for April 25, the pharmaceutical and agricultural company stated that the authorized capital 2025 should only be used if absolutely necessary. There are currently no specific plans in this regard. However, it cannot be ruled out that the Company may be forced to increase its share capital at short notice in the future, for example, in order to reach a potential future settlement with plaintiffs in the United States.

BioNxt Solutions – Top Performer unstoppable

While Bayer's stock has been on a downward trend for years, the shares of innovative life sciences company BioNxt Solutions, which focuses on next-generation drug delivery technologies, diagnostic screening systems, and the development of active pharmaceutical ingredients, continue to thrive. Since the low of CAD 0.17 in June 2024, the stock performance has surged by a solid 229% to its current price of CAD 0.56.

The fact that this is unlikely to be the end of the road is illustrated by the 90-day plan for the accelerated commercialization of its pipeline, which the experienced management published in mid-February. The completion of patent applications at the national level in the key target regions of the US, Canada, Australia, Europe, and Japan marks a milestone for BioNxt. It lays the foundation for corresponding marketing opportunities for the sublingual drug products currently being developed by the Company for the treatment of autoimmune diseases such as multiple sclerosis, myasthenia gravis, lupus nephritis, and rheumatoid arthritis.

In addition, BioNxt plans to enter the multi-billion dollar longevity and anti-aging products sector soon. Co-founder and CEO Hugh Rogers and his team are developing innovative sublingual orodispersible films and enteric-coated tablets containing active pharmaceutical ingredients. Early studies suggest these products could slow ovarian aging, extend fertility duration, and contribute to healthier aging. These product developments aim to meet the growing demand for effective anti-aging therapies.

Novo Nordisk – Interim rally over?

The share price of last year's stock market star is not really taking off. After the June 2024 high of USD 148.15, the Novo share price corrected by more than 40% to its current USD 87.17. After interim lows in March at USD 77, a bear market rally took place, but this is currently threatening to tip over again. The year's high of USD 93.80 in February was sold off, and both MACD and RSI gave sell signals again in the past trading week.

Meanwhile, the market for weight loss drugs is becoming increasingly competitive. Rival Eli Lilly has already scored points by introducing LillyDirect, its online pharmacy, which allows products to be purchased directly from the Company. With NovoCare, the Danes are now following suit.

NovoCare has reduced the price of Wegovy to USD 499 per month. This pricing is particularly advantageous for patients who are either uninsured or whose insurance does not cover obesity medications. With this pricing policy, Novo Nordisk intends to facilitate access and consolidate its position in the market.

Meanwhile, Swiss bank UBS reaffirms its "Buy" rating on Novo Nordisk, noting that the prescription trend for GLP-1 class weight loss drugs has recovered well. The price target was left at DKK 750, equivalent to USD 108.94.

The pharmaceutical and agricultural giant Bayer shocked investors with an announced capital increase. Novo Nordisk is fighting back against growing competition by launching a direct sales organization. BioNxt is planning to enter the billion-dollar anti-aging market.